Glenmark launches Type 2 Diabetes fixed-dose combination drug in India
image for illustrative purpose
Glenmark has become the first company to launch Remogliflozin + Vildagliptin + Metformin fixed-dose combination (FDC) drug at an affordable price for adults with Type 2 Diabetes. India is the first country to get access to this FDC drug. Glenmark received approval for the drug from the Drug Controller General of India (DCGI) for manufacturing and marketing in late September 2021.
Glenmark's new drug combines two or more active drugs in a single dosage form and can tackle most of the pathophysiology in managing uncontrolled Type 2 Diabetes. Glenmark, in its statement, said that it has been at the forefront in providing access to the latest treatments at a low cost for patients with diabetes in India. According to the International Diabetes Federation (IDF), around 77 million adults are living with diabetes in India.
"Globally, SGLT2i + DPP4i + Metformin FDCs are emerging as a preferred treatment for the management of Type 2 diabetes. Diabetes is a key focus area for Glenmark, and we have been at the forefront in providing access to the latest treatment options to diabetes patients in India," said Alok Malik, Group Vice President & Business Head, India Formulations.
